Reviva Pharmaceuticals GAAP EPS of -$0.06

* Reviva Pharmaceuticals press release [https://seekingalpha.com/pr/20307320-reviva-reports-third-quarter-2025-financial-results-and-recent-business-highlights] (RVPH [https://seekingalpha.com/symbol/RVPH]): Q3 GAAP EPS of -$0.06.
* As of September 30, 2025, the Company’s cash and cash equivalents totaled approximately $13.2 million compared to approximately $13.5 million as of December 31, 2024.

MORE ON REVIVA PHARMACEUTICALS

* Reviva Pharmaceuticals announces pricing of $9M public offering [https://seekingalpha.com/news/4496408-reviva-pharmaceuticals-announces-pricing-of-9m-public-offering]
* Reviva Pharmaceuticals announces proposed public offering [https://seekingalpha.com/news/4496355-reviva-pharmaceuticals-announces-proposed-public-offering]
* Seeking Alpha’s Quant Rating on Reviva Pharmaceuticals [https://seekingalpha.com/symbol/RVPH/ratings/quant-ratings]
* Historical earnings data for Reviva Pharmaceuticals [https://seekingalpha.com/symbol/RVPH/earnings]
* Financial information for Reviva Pharmaceuticals [https://seekingalpha.com/symbol/RVPH/income-statement]